Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Inclusion Criteria: * Histologically or cytologically proven squamous cell carcinoma of the head and neck not amenable to curative intent therapy. * Presence of measurable tumor lesions per RECIST criteria v1.1 * Life expectancy greater than 12 weeks. * Adequate hematologic, hepatic, and renal function * Negative serum or urine pregnancy test for women of child bearing potential Exclusion Criteria: * Prior therapy with an EGFR inhibitor or PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting * Uncontrolled central nervous system metastases (stable metastases permitted) * Chemotherapy 28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment. * History of other malignancies, * Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of \>10 mg/day of prednisone or equivalent) * Prior organ transplantation * Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).